Global Lupus Market: Industry Analysis and Forecast (2021-2027) by Technique, Product, End-user and Region

Global Lupus Market was valued at US$ 1.88 Bn. in 2020 and is expected to reach US$ 4.3 Bn. by 2027, at a CAGR of 12.41% during a forecast period.

Global Lupus Market Overview:

The global lupus market was valued at US$ 1.88 Bn. in 2020. Lupus is a chronic autoimmune disease that causes inflammation all over the body. In patients with lupus, the immune system attacks its own tissues and can damage several parts of the body including kidney, heart, skin, joints, lungs, brain, and blood vessels. Lupus patients may be at higher risk of developing severe infections if they develop COVID-19. Global Lupus Market To know about the Research Methodology :- Request Free Sample Report The report has covered the market trends from 2016 to forecast the market through 2027. 2020 is considered a base year. Special attention is given to 2020 and effect of lockdown on the demand and supply, and also the impact of lockdown for next two years on the market. Some companies have done well in lockdown also and specific strategic analysis of those companies is done in the report.

Global Lupus Market Dynamics:

The market for lupus is growing at breakneck speed across the world because of the surging prevalence of lupus and the ongoing medical developments in treating systemic lupus erythematous. The increased R&D activities for lupus can be considered a driving factor. Throughout the world, approximately 5 million people suffer from lupus and 70% of the total cases are systemic lupus erythematous. As per the Lupus Foundation of America, approximately 1.5 million Americans have a form of lupus, and around 16,000 new cases are reported yearly in the Americans. However, stringent regulatory guidelines for new drugs and the cost restraint are expected to be among the primary hindrance. Likewise, the MMR report covers all the trends and technologies playing a major role in the growth of the lupus market over the 2021-2027. It highlights the drivers, restraints, and opportunities expected to influence the lupus market growth during the forecast period. Global Lupus Market Lupus is a systemic autoimmune illness that produces widespread inflammation. The immune system targets healthy cells and tissues in lupus patients, causing damage to numerous regions of the body, including the skin, joints, kidneys, heart, lungs, blood vessels, and brain. During the projection period, factors such as rising lupus prevalence, ongoing medical developments in the treatment of systemic lupus erythematous, and increased research and development efforts are projected to fuel lupus market growth. The Lupus Foundation of America estimates that 1.5 million Americans have lupus, with 16,000 new cases recorded each year in the Americas. Despite the drivers, market growth may be hampered by obstacles such as rigorous government regulation and rising lupus drug prices over the assessment period. In the lupus market nowadays, there are a huge number of enterprises. The creation of new products and the introduction of new products are involving the major market players. For example, GlaxoSmithKline got FDA approval in July 2019 for a novel Benlysta self-injectable formulation for the treatment of adult patients with systemic lupus erythematous.

Global Lupus Market segment analysis:

The Global Lupus Market is segmented into Technique, Product, and End-user. Based on technique, the systemic lupus erythematous segment held largest share of xx% in 2020, owing to treatment can help you manage your symptoms, avoid flare-ups, and avoid other lupus-related health issues. No steroidal anti-inflammatory drugs (NSAIDs) are the most widely utilised medications to treat lupus (NSAIDs). Pain, edoema, and fever associated with lupus can be treated with over-the-counter NSAIDs such as naproxen sodium (Aleve) and ibuprofen (Advil, Motrin IB, and others). Global Lupus MarketBased on product, the biologics segment is currently leading the market, with a CAGR of 7.2% expected during the forecast period. The introduction of new biologics with improved efficacy, such as Benlysta and Rituximab, is projected to drive category growth. Benlysta is used to treat moderate SLE (Systemic Lupus Erythematous), however its safety and efficiency in severe Lupus are still unknown. Immunosuppressants and corticosteroids, on the other hand, have a long list of negative effects. Rituximab, on the other hand, has none. Global Lupus Market

Global Lupus Market Regional Insight:

North America’s lupus market was valued at US$ 12 Mn. in 2020 and is expected to reach a value of US$ 89 Mn. by 2027, with a CAGR of 50% during the forecast period. This is owing to the availability of reimbursement, growing demand for better treatment options, rising prevalence of lupus, government initiatives for lupus. Moreover, the developed healthcare infrastructure and accessibility to biologics are likely to contribute to the lupus market growth in the region. The U.S. has the highest number of people diagnosed from LN in 2019, followed by the U.K. and Japan. The prevalence of lupus nephritis in the AAPC SLE patient population is much higher than in Caucasians. Therefore, it represents a large and well-defined market opportunity with very little competition and is expected to be worth US$ 89 billion by 2020 at a CAGR of 29 %. The objective of the report is to present a comprehensive analysis of the global Lupus market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the global Lupus market dynamics, structure by analyzing the market segments and projects the global market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global market make the report investor’s guide.

Global Lupus Market Scope: Inquire before buying

Global Lupus Market
Report Coverage Details
Base Year: 2020 Forecast Period: 2021-2027
Historical Data: 2016 to 2020 Market Size in 2020: US $ 1.88 Bn.
Forecast Period 2021 to 2027 CAGR: 12.41% Market Size in 2027: US $ 4.3 Bn.
Segments Covered: by Technique • Systemic Lupus Erythematosus • Cutaneous Lupus Erythematosus • Drug-Induced Lupus Erythematosus • Neonatal Lupus
by Product • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) • Antimalarial Drugs • Corticosteroids • Immunosuppressants • Biologics • Others
by End User • Hospital & Clinics • Diagnostic Laboratories • Other

Global Lupus Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America

Global Lupus Market Key Players

Aurinia Pharmaceuticals • Bristol-Myers Squibb • Cadila Healthcare • GlaxoSmithKline plc • Mylan N.V. • F. Hoffmann-La • Pfizer, Inc. • Sanofi • Lycera Corporation • Merck KGaA • Eli Lily • ImmuPharma LLC • Anthera Pharmaceuticals • Lycera • Sandoz International GmbH • Novartis AG, • Bayer AG • Trinity Biotech Frequently Asked Questions: 1. Which region has the largest share in Global Lupus Market? Ans: North America region holds the highest share in 2020. 2. What is the growth rate of Global Lupus Market? Ans: The Global Lupus Market is growing at a CAGR of 12.41 % during forecasting period 2021-2027. 3. What segments are covered in Global Lupus market? Ans: Global Lupus Market is segmented into technique, product, end-user and region. 4. Who are the key players in Global Lupus market? Ans: The important key players in the Global Lupus Market are – Aurinia Pharmaceuticals, Bristol-Myers Squibb, Cadila Healthcare, GlaxoSmithKline plc, Mylan N.V., F. Hoffmann-La , Pfizer, Inc., Sanofi, Lycera Corporation, Merck KGaA, Eli Lily , ImmuPharma LLC, Anthera Pharmaceuticals. 5. What is the study period of this market? Ans: The Global Lupus Market is studied from 2020 to 2027.
Global Lupus Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Lupus Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Lupus Market Analysis and Forecast 6.1. Lupus Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Lupus Market Analysis and Forecast, By Technique 7.1. Introduction and Definition 7.2. Key Findings 7.3. Lupus Market Value Share Analysis, By Technique 7.4. Lupus Market Size (US$ Bn) Forecast, By Technique 7.5. Lupus Market Analysis, By Technique 7.6. Lupus Market Attractiveness Analysis, By Technique 8. Global Lupus Market Analysis and Forecast, By Product 8.1. Introduction and Definition 8.2. Key Findings 8.3. Lupus Market Value Share Analysis, By Product 8.4. Lupus Market Size (US$ Bn) Forecast, By Product 8.5. Lupus Market Analysis, By Product 8.6. Lupus Market Attractiveness Analysis, By Product 9. Global Lupus Market Analysis and Forecast, By End User 9.1. Introduction and Definition 9.2. Key Findings 9.3. Lupus Market Value Share Analysis, By End User 9.4. Lupus Market Size (US$ Bn) Forecast, By End User 9.5. Lupus Market Analysis, By End User 9.6. Lupus Market Attractiveness Analysis, By End User 10. Global Lupus Market Analysis, by Region 10.1. Lupus Market Value Share Analysis, by Region 10.2. Lupus Market Size (US$ Bn) Forecast, by Region 10.3. Lupus Market Attractiveness Analysis, by Region 11. North America Lupus Market Analysis 11.1. Key Findings 11.2. North America Lupus Market Overview 11.3. North America Lupus Market Value Share Analysis, By Technique 11.4. North America Lupus Market Forecast, By Technique 11.4.1. Systemic Lupus Erythematosus 11.4.2. Cutaneous Lupus Erythematosus 11.4.3. Drug-Induced Lupus Erythematosus 11.4.4. Neonatal Lupus 11.5. North America Lupus Market Value Share Analysis, By Product 11.6. North America Lupus Market Forecast, By Product 11.6.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 11.6.2. Antimalarial Drugs 11.6.3. Corticosteroids 11.6.4. Immunosuppressants 11.6.5. Biologics 11.6.6. Others 11.7. North America Lupus Market Value Share Analysis, By End User 11.8. North America Lupus Market Forecast, By End User 11.8.1. Hospital & Clinics 11.8.2. Diagnostic Laboratories 11.8.3. Other 11.9. North America Lupus Market Value Share Analysis, by Country 11.10. North America Lupus Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Lupus Market Analysis, by Country 11.12. U.S. Lupus Market Forecast, By Technique 11.12.1. Systemic Lupus Erythematosus 11.12.2. Cutaneous Lupus Erythematosus 11.12.3. Drug-Induced Lupus Erythematosus 11.12.4. Neonatal Lupus 11.13. U.S. Lupus Market Forecast, By Product 11.13.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 11.13.2. Antimalarial Drugs 11.13.3. Corticosteroids 11.13.4. Immunosuppressants 11.13.5. Biologics 11.13.6. Others 11.14. U.S. Lupus Market Forecast, By End User 11.14.1. Hospital & Clinics 11.14.2. Diagnostic Laboratories 11.14.3. Other 11.15. Canada Lupus Market Forecast, By Technique 11.15.1. Systemic Lupus Erythematosus 11.15.2. Cutaneous Lupus Erythematosus 11.15.3. Drug-Induced Lupus Erythematosus 11.15.4. Neonatal Lupus 11.16. Canada Lupus Market Forecast, By Product 11.16.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 11.16.2. Antimalarial Drugs 11.16.3. Corticosteroids 11.16.4. Immunosuppressants 11.16.5. Biologics 11.16.6. Others 11.17. Canada Lupus Market Forecast, By End User 11.17.1. Hospital & Clinics 11.17.2. Diagnostic Laboratories 11.17.3. Other 11.18. North America Lupus Market Attractiveness Analysis 11.18.1. By Technique 11.18.2. By Product 11.18.3. By End User 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Lupus Market Analysis 12.1. Key Findings 12.2. Europe Lupus Market Overview 12.3. Europe Lupus Market Value Share Analysis, By Technique 12.4. Europe Lupus Market Forecast, By Technique 12.4.1. Systemic Lupus Erythematosus 12.4.2. Cutaneous Lupus Erythematosus 12.4.3. Drug-Induced Lupus Erythematosus 12.4.4. Neonatal Lupus 12.5. Europe Lupus Market Value Share Analysis, By Product 12.6. Europe Lupus Market Forecast, By Product 12.6.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 12.6.2. Antimalarial Drugs 12.6.3. Corticosteroids 12.6.4. Immunosuppressants 12.6.5. Biologics 12.6.6. Others 12.7. Europe Lupus Market Value Share Analysis, By End User 12.8. Europe Lupus Market Forecast, By End User 12.8.1. Hospital & Clinics 12.8.2. Diagnostic Laboratories 12.8.3. Other 12.9. Europe Lupus Market Value Share Analysis, by Country 12.10. Europe Lupus Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Lupus Market Analysis, by Country 12.12. Germany Lupus Market Forecast, By Technique 12.12.1. Systemic Lupus Erythematosus 12.12.2. Cutaneous Lupus Erythematosus 12.12.3. Drug-Induced Lupus Erythematosus 12.12.4. Neonatal Lupus 12.13. Germany Lupus Market Forecast, By Product 12.13.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 12.13.2. Antimalarial Drugs 12.13.3. Corticosteroids 12.13.4. Immunosuppressants 12.13.5. Biologics 12.13.6. Others 12.14. Germany Lupus Market Forecast, By End User 12.14.1. Hospital & Clinics 12.14.2. Diagnostic Laboratories 12.14.3. Other 12.15. U.K. Lupus Market Forecast, By Technique 12.15.1. Systemic Lupus Erythematosus 12.15.2. Cutaneous Lupus Erythematosus 12.15.3. Drug-Induced Lupus Erythematosus 12.15.4. Neonatal Lupus 12.16. U.K. Lupus Market Forecast, By Product 12.16.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 12.16.2. Antimalarial Drugs 12.16.3. Corticosteroids 12.16.4. Immunosuppressants 12.16.5. Biologics 12.16.6. Others 12.17. U.K. Lupus Market Forecast, By End User 12.17.1. Hospital & Clinics 12.17.2. Diagnostic Laboratories 12.17.3. Other 12.18. France Lupus Market Forecast, By Technique 12.18.1. Systemic Lupus Erythematosus 12.18.2. Cutaneous Lupus Erythematosus 12.18.3. Drug-Induced Lupus Erythematosus 12.18.4. Neonatal Lupus 12.19. France Lupus Market Forecast, By Product 12.19.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 12.19.2. Antimalarial Drugs 12.19.3. Corticosteroids 12.19.4. Immunosuppressants 12.19.5. Biologics 12.19.6. Others 12.20. France Lupus Market Forecast, By End User 12.20.1. Hospital & Clinics 12.20.2. Diagnostic Laboratories 12.20.3. Other 12.21. Italy Lupus Market Forecast, By Technique 12.21.1. Systemic Lupus Erythematosus 12.21.2. Cutaneous Lupus Erythematosus 12.21.3. Drug-Induced Lupus Erythematosus 12.21.4. Neonatal Lupus 12.22. Italy Lupus Market Forecast, By Product 12.22.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 12.22.2. Antimalarial Drugs 12.22.3. Corticosteroids 12.22.4. Immunosuppressants 12.22.5. Biologics 12.22.6. Others 12.23. Italy Lupus Market Forecast, By End User 12.23.1. Hospital & Clinics 12.23.2. Diagnostic Laboratories 12.23.3. Other 12.24. Spain Lupus Market Forecast, By Technique 12.24.1. Systemic Lupus Erythematosus 12.24.2. Cutaneous Lupus Erythematosus 12.24.3. Drug-Induced Lupus Erythematosus 12.24.4. Neonatal Lupus 12.25. Spain Lupus Market Forecast, By Product 12.25.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 12.25.2. Antimalarial Drugs 12.25.3. Corticosteroids 12.25.4. Immunosuppressants 12.25.5. Biologics 12.25.6. Others 12.26. Spain Lupus Market Forecast, By End User 12.26.1. Hospital & Clinics 12.26.2. Diagnostic Laboratories 12.26.3. Other 12.27. Rest of Europe Lupus Market Forecast, By Technique 12.27.1. Systemic Lupus Erythematosus 12.27.2. Cutaneous Lupus Erythematosus 12.27.3. Drug-Induced Lupus Erythematosus 12.27.4. Neonatal Lupus 12.28. Rest of Europe Lupus Market Forecast, By Product 12.28.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 12.28.2. Antimalarial Drugs 12.28.3. Corticosteroids 12.28.4. Immunosuppressants 12.28.5. Biologics 12.28.6. Others 12.29. Rest Of Europe Lupus Market Forecast, By End User 12.29.1. Hospital & Clinics 12.29.2. Diagnostic Laboratories 12.29.3. Other 12.30. Europe Lupus Market Attractiveness Analysis 12.30.1. By Technique 12.30.2. By Product 12.30.3. By End User 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Lupus Market Analysis 13.1. Key Findings 13.2. Asia Pacific Lupus Market Overview 13.3. Asia Pacific Lupus Market Value Share Analysis, By Technique 13.4. Asia Pacific Lupus Market Forecast, By Technique 13.4.1. Systemic Lupus Erythematosus 13.4.2. Cutaneous Lupus Erythematosus 13.4.3. Drug-Induced Lupus Erythematosus 13.4.4. Neonatal Lupus 13.5. Asia Pacific Lupus Market Value Share Analysis, By Product 13.6. Asia Pacific Lupus Market Forecast, By Product 13.6.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 13.6.2. Antimalarial Drugs 13.6.3. Corticosteroids 13.6.4. Immunosuppressants 13.6.5. Biologics 13.6.6. Others 13.7. Asia Pacific Lupus Market Value Share Analysis, By End User 13.8. Asia Pacific Lupus Market Forecast, By End User 13.8.1. Hospital & Clinics 13.8.2. Diagnostic Laboratories 13.8.3. Other 13.9. Asia Pacific Lupus Market Value Share Analysis, by Country 13.10. Asia Pacific Lupus Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Lupus Market Analysis, by Country 13.12. China Lupus Market Forecast, By Technique 13.12.1. Systemic Lupus Erythematosus 13.12.2. Cutaneous Lupus Erythematosus 13.12.3. Drug-Induced Lupus Erythematosus 13.12.4. Neonatal Lupus 13.13. China Lupus Market Forecast, By Product 13.13.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 13.13.2. Antimalarial Drugs 13.13.3. Corticosteroids 13.13.4. Immunosuppressants 13.13.5. Biologics 13.13.6. Others 13.14. China Lupus Market Forecast, By End User 13.14.1. Hospital & Clinics 13.14.2. Diagnostic Laboratories 13.14.3. Other 13.15. India Lupus Market Forecast, By Technique 13.15.1. Systemic Lupus Erythematosus 13.15.2. Cutaneous Lupus Erythematosus 13.15.3. Drug-Induced Lupus Erythematosus 13.15.4. Neonatal Lupus 13.16. India Lupus Market Forecast, By Product 13.16.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 13.16.2. Antimalarial Drugs 13.16.3. Corticosteroids 13.16.4. Immunosuppressants 13.16.5. Biologics 13.16.6. Others 13.17. India Lupus Market Forecast, By End User 13.17.1. Hospital & Clinics 13.17.2. Diagnostic Laboratories 13.17.3. Other 13.18. Japan Lupus Market Forecast, By Technique 13.18.1. Systemic Lupus Erythematosus 13.18.2. Cutaneous Lupus Erythematosus 13.18.3. Drug-Induced Lupus Erythematosus 13.18.4. Neonatal Lupus 13.19. Japan Lupus Market Forecast, By Product 13.19.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 13.19.2. Antimalarial Drugs 13.19.3. Corticosteroids 13.19.4. Immunosuppressants 13.19.5. Biologics 13.19.6. Others 13.20. Japan Lupus Market Forecast, By End User 13.20.1. Hospital & Clinics 13.20.2. Diagnostic Laboratories 13.20.3. Other 13.21. ASEAN Lupus Market Forecast, By Technique 13.21.1. Systemic Lupus Erythematosus 13.21.2. Cutaneous Lupus Erythematosus 13.21.3. Drug-Induced Lupus Erythematosus 13.21.4. Neonatal Lupus 13.22. ASEAN Lupus Market Forecast, By Product 13.22.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 13.22.2. Antimalarial Drugs 13.22.3. Corticosteroids 13.22.4. Immunosuppressants 13.22.5. Biologics 13.22.6. Others 13.23. ASEAN Lupus Market Forecast, By End User 13.23.1. Hospital & Clinics 13.23.2. Diagnostic Laboratories 13.23.3. Other 13.24. Rest of Asia Pacific Lupus Market Forecast, By Technique 13.24.1. Systemic Lupus Erythematosus 13.24.2. Cutaneous Lupus Erythematosus 13.24.3. Drug-Induced Lupus Erythematosus 13.24.4. Neonatal Lupus 13.25. Rest of Asia Pacific Lupus Market Forecast, By Product 13.25.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 13.25.2. Antimalarial Drugs 13.25.3. Corticosteroids 13.25.4. Immunosuppressants 13.25.5. Biologics 13.25.6. Others 13.26. Rest of Asia Pacific Lupus Market Forecast, By End User 13.26.1. Hospital & Clinics 13.26.2. Diagnostic Laboratories 13.26.3. Other 13.27. Asia Pacific Lupus Market Attractiveness Analysis 13.27.1. By Technique 13.27.2. By Product 13.27.3. By End User 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Lupus Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Lupus Market Overview 14.3. Middle East & Africa Lupus Market Value Share Analysis, By Technique 14.4. Middle East & Africa Lupus Market Forecast, By Technique 14.4.1. Systemic Lupus Erythematosus 14.4.2. Cutaneous Lupus Erythematosus 14.4.3. Drug-Induced Lupus Erythematosus 14.4.4. Neonatal Lupus 14.5. Middle East & Africa Lupus Market Value Share Analysis, By Product 14.6. Middle East & Africa Lupus Market Forecast, By Product 14.6.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 14.6.2. Antimalarial Drugs 14.6.3. Corticosteroids 14.6.4. Immunosuppressants 14.6.5. Biologics 14.6.6. Others 14.7. Middle East & Africa Lupus Market Value Share Analysis, By End User 14.8. Middle East & Africa Lupus Market Forecast, By End User 14.8.1. Hospital & Clinics 14.8.2. Diagnostic Laboratories 14.8.3. Other 14.9. Middle East & Africa Lupus Market Value Share Analysis, by Country 14.10. Middle East & Africa Lupus Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Lupus Market Analysis, by Country 14.12. GCC Lupus Market Forecast, By Technique 14.12.1. Systemic Lupus Erythematosus 14.12.2. Cutaneous Lupus Erythematosus 14.12.3. Drug-Induced Lupus Erythematosus 14.12.4. Neonatal Lupus 14.13. GCC Lupus Market Forecast, By Product 14.13.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 14.13.2. Antimalarial Drugs 14.13.3. Corticosteroids 14.13.4. Immunosuppressants 14.13.5. Biologics 14.13.6. Others 14.14. GCC Lupus Market Forecast, By End User 14.14.1. Hospital & Clinics 14.14.2. Diagnostic Laboratories 14.14.3. Other 14.15. South Africa Lupus Market Forecast, By Technique 14.15.1. Systemic Lupus Erythematosus 14.15.2. Cutaneous Lupus Erythematosus 14.15.3. Drug-Induced Lupus Erythematosus 14.15.4. Neonatal Lupus 14.16. South Africa Lupus Market Forecast, By Product 14.16.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 14.16.2. Antimalarial Drugs 14.16.3. Corticosteroids 14.16.4. Immunosuppressants 14.16.5. Biologics 14.16.6. Others 14.17. South Africa Lupus Market Forecast, By End User 14.17.1. Hospital & Clinics 14.17.2. Diagnostic Laboratories 14.17.3. Other 14.18. Rest of Middle East & Africa Lupus Market Forecast, By Technique 14.18.1. Systemic Lupus Erythematosus 14.18.2. Cutaneous Lupus Erythematosus 14.18.3. Drug-Induced Lupus Erythematosus 14.18.4. Neonatal Lupus 14.19. Rest of Middle East & Africa Lupus Market Forecast, By Product 14.19.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 14.19.2. Antimalarial Drugs 14.19.3. Corticosteroids 14.19.4. Immunosuppressants 14.19.5. Biologics 14.19.6. Others 14.20. Middle East & Africa Lupus Market Forecast, By End User 14.20.1. Hospital & Clinics 14.20.2. Diagnostic Laboratories 14.20.3. Other 14.21. Middle East & Africa Lupus Market Attractiveness Analysis 14.21.1. By Technique 14.21.2. By Product 14.21.3. By End User 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Lupus Market Analysis 15.1. Key Findings 15.2. South America Lupus Market Overview 15.3. South America Lupus Market Value Share Analysis, By Technique 15.4. South America Lupus Market Forecast, By Technique 15.4.1. Systemic Lupus Erythematosus 15.4.2. Cutaneous Lupus Erythematosus 15.4.3. Drug-Induced Lupus Erythematosus 15.4.4. Neonatal Lupus 15.5. South America Lupus Market Value Share Analysis, By Product 15.6. South America Lupus Market Forecast, By Product 15.6.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 15.6.2. Antimalarial Drugs 15.6.3. Corticosteroids 15.6.4. Immunosuppressants 15.6.5. Biologics 15.6.6. Others 15.7. South America Lupus Market Value Share Analysis, By End User 15.8. South America Lupus Market Forecast, By End User 15.8.1. Hospital & Clinics 15.8.2. Diagnostic Laboratories 15.8.3. Other 15.9. South America Lupus Market Value Share Analysis, by Country 15.10. South America Lupus Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Lupus Market Analysis, by Country 15.12. Brazil Lupus Market Forecast, By Technique 15.12.1. Systemic Lupus Erythematosus 15.12.2. Cutaneous Lupus Erythematosus 15.12.3. Drug-Induced Lupus Erythematosus 15.12.4. Neonatal Lupus 15.13. Brazil Lupus Market Forecast, By Product 15.13.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 15.13.2. Antimalarial Drugs 15.13.3. Corticosteroids 15.13.4. Immunosuppressants 15.13.5. Biologics 15.13.6. Others 15.14. Brazil Lupus Market Forecast, By End User 15.14.1. Hospital & Clinics 15.14.2. Diagnostic Laboratories 15.14.3. Other 15.15. Mexico Lupus Market Forecast, By Technique 15.15.1. Systemic Lupus Erythematosus 15.15.2. Cutaneous Lupus Erythematosus 15.15.3. Drug-Induced Lupus Erythematosus 15.15.4. Neonatal Lupus 15.16. Mexico Lupus Market Forecast, By Product 15.16.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 15.16.2. Antimalarial Drugs 15.16.3. Corticosteroids 15.16.4. Immunosuppressants 15.16.5. Biologics 15.16.6. Others 15.17. Mexico Lupus Market Forecast, By End User 15.17.1. Hospital & Clinics 15.17.2. Diagnostic Laboratories 15.17.3. Other 15.18. Rest of South America Lupus Market Forecast, By Technique 15.18.1. Systemic Lupus Erythematosus 15.18.2. Cutaneous Lupus Erythematosus 15.18.3. Drug-Induced Lupus Erythematosus 15.18.4. Neonatal Lupus 15.19. Rest of South America Lupus Market Forecast, By Product 15.19.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 15.19.2. Antimalarial Drugs 15.19.3. Corticosteroids 15.19.4. Immunosuppressants 15.19.5. Biologics 15.19.6. Others 15.20. Rest of South America Lupus Market Forecast, By End User 15.20.1. Hospital & Clinics 15.20.2. Diagnostic Laboratories 15.20.3. Other 15.21. South America Lupus Market Attractiveness Analysis 15.21.1. By Technique 15.21.2. By Product 15.21.3. By End User 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Aurinia Pharmaceuticals, Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Web Basediness Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Bristol-Myers Squibb Company 16.3.3. Cadila Healthcare 16.3.4. GlaxoSmithKline plc 16.3.5. Mylan N.V. 16.3.6. F. Hoffmann-La Roche AG 16.3.7. Pfizer, Inc. 16.3.8. Sanofi 16.3.9. Lycera Corporation 16.3.10. Merck KGaA 16.3.11. Eli Lily and Company 16.3.12. ImmuPharma LLC 16.3.13. Anthera Pharmaceuticals, Inc. 16.3.14. Lycera 16.3.15. Sandoz International GmbH 16.3.16. Novartis AG, 16.3.17. Bayer AG 16.3.18. Zydus Cadila 16.3.19. Trinity Biotech 17. Primary Key Insights

About This Report

Report ID65753
Category Healthcare
Published DateJuly 2020
Updated DateSept 2021
Contact Us